Champions Oncology is the rare micro-cap where the most interesting development this week is not what bears are doing — it's what they have stopped doing in the options market, even as short positions quietly build.
The shift in options sentiment has been dramatic. The put/call ratio has collapsed to 0.15, nearly 1.2 standard deviations below its 20-day average of 3.49. That average itself tells the story: as recently as mid-March, the PCR reached 37.35 — meaning traders were holding roughly 37 puts for every call. Now the ratio has inverted sharply, with calls dominating the options book. The reading has held steady at that low level for four consecutive sessions, suggesting the flip is not a one-day anomaly.
Short interest, however, tells a different story from the options book. Shorts have been rebuilding. The estimated short position rose 13% across the week to roughly 85,100 shares, after touching a recent low in the mid-70,000s earlier in April. That said, the absolute level remains modest — 0.6% of the free float — so this is not a story of a crowded short book. Borrow conditions reinforce that read: cost to borrow is just 0.65%, down sharply from a brief spike to 2.3% on April 20. Availability in the lending pool is loose. There is no squeeze pressure visible in the financing market.
The Street picture is thin and must be treated carefully. Craig-Hallum raised its target to $12.00 back in March 2025 — over a year ago — and that remains the only published target. With the stock trading near $5.91, the implied upside is substantial on paper, but the data is stale and should not be read as a live call. No recent analyst activity has been recorded. The ORTEX short score has drifted higher to 43.99, a two-week high, while the utilization rank of 70 (percentile) suggests short interest is elevated relative to history even if the absolute level is low.
Catalysts have been in motion. Champions Oncology presented new data on predicting treatment response and resistance at the AACR 2026 annual meeting earlier in April — a development that likely contributed to the sentiment reset in the options market. The most recent earnings prints both produced positive next-day moves: the March 13 event delivered an 8.9% gain on the day and a 5.1% gain over the following five sessions; the March 12 release added 3.4% on the day and 5.1% over the week. The stock itself is up 1.9% on the week and 3.0% on the month, closing at $5.91 on Tuesday.
What to watch: whether the call-dominated options positioning holds into any follow-on scientific catalysts from the AACR cycle, and whether the steady short rebuild continues toward the April highs around 89,500 shares — which would test whether rising bearish positioning and bullish options sentiment can coexist much longer.
See the live data behind this article on ORTEX.
Open CSBR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
